Bayer Aktiengesellschaft (BAYN.DE): analysis and signal as of September 4, 2026

Published on September 5, 2026 at 07:11 · Updated on September 5, 2026 at 07:11 · by Aurélien Ambert, QDNA

Exchange : Xetra · Sector : Healthcare

In short

The signal is weak on Bayer Aktiengesellschaft (BAYN.DE) as of 4 September 2026. The main reason lies in the binary uncertainty around the Crop/glyphosate divestiture and the Roundup case, which delays the re-rating despite a deep-value discount.

Current signal: weak (vote 3/3)
Deterministic score: -1.5 → signal expected by the scale : weak (September 10, 2026)
Layers: fundamentals : neutral, price : neutral, risks : negative, fundamentals : négatif, price : positive, risks : neutral

Triggered rules

Rule	Weight
penalizes an asset whose net debt/EBITDA exceeds the threshold, and the use of leverage (margin/lombard)	-2.5
moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation)	+0.5
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

Bayer offers deep structural value, but the share could remain a trap as long as the Crop/glyphosate divestiture has not been completed and the Roundup litigation remains open. The market prices in a risk premium linked to two binary outcomes, with no formal catalyst likely to reduce the discount. The six-month intraday momentum appears encouraging, but real-time data remain unavailable to confirm this dynamic.

Bull case

The completion of the Crop/glyphosate divestiture, combined with the deleveraging program aimed at a net debt-to-EBITDA ratio below 3,0 times by end-2026, could compress the value discount. This compression would be comparable to the one observed at Novartis after the Sandoz spin-off.

Bear case

The Roundup trial is not over. The net debt-to-EBITDA ratio remains structurally high, around 3,5 times. Exposure to the dollar and to the crop cycle suffers a double macroeconomic penalty, with the CLI DEU indicator at -0,17 over three months. The asundexian pipeline is scheduled for an FDA readout in 2026, which keeps the value-trap scenario alive.

Scenarios

The bullish scenario, with 30 per cent probability, targets a share price of EUR 65 if the Crop divestiture succeeds, the ratio falls below 3,0 times and the litigation is concluded. The central scenario, with 50 per cent probability, places the share price in a range of EUR 42 to EUR 55 during the course of the proceedings, with increased volatility before the BCE releases and the CLARITY results in mid-September. The bearish scenario, with 20 per cent probability, results in a maximum loss of 35 per cent, toward EUR 32, if the divestiture fails, if a new Roundup provision is booked, or if asundexian fails.

Risks

The central risk is the non-completion of the Crop/glyphosate divestiture, combined with potential additional provisions in the Roundup case. An unfavourable FDA opinion on asundexian in 2026 would constitute an additional shock. The combination of these factors would keep the stock in a value-trap configuration and produce an amplified loss, consistent with the bearish scenario.

Signal history (last 12 months)

Date	Signal	New fact
September 4, 2026	weak (3/3)	No new quantified fact is available in the environment. The verdict is consistent with the known state.

Frequently asked questions

Why does the signal remain weak despite the value discount?

The signal is weak because two major uncertainties weigh on the stock. The divestiture of the Crop/glyphosate operations has not been completed and the Roundup litigation is not closed. These two matters create a binary situation. The market therefore values the stock at a discount, but unlocking value depends on a formal and verifiable catalyst, such as the signing of an agreement or the outcome of a ruling.

What is Bayer's deleveraging target for end-2026?

The company targets a net debt-to-EBITDA ratio below 3,0 times at the end of 2026. This target accompanies the divestiture of the Crop/glyphosate businesses. Reaching this target could reduce the value discount, by analogy with what was observed at Novartis after the Sandoz spin-off. The deleveraging program constitutes a central lever of the bullish scenario and conditions part of investor confidence.

What are the consequences of an asundexian failure at the FDA?

Asundexian is a pipeline asset subject to an FDA readout in 2026. A failure in this process would constitute a downside risk and could lead to a decline in the stock. The bearish scenario links this failure to a maximum loss of 35 per cent, in combination with other unfavourable factors such as the absence of completion of the Crop/glyphosate divestiture.

What does the net debt-to-EBITDA ratio of about 3,5 times mean?

The net debt-to-EBITDA ratio measures a company's ability to repay its debt out of operating profit. A level of about 3,5 times is structurally high for Bayer. This level results from the Monsanto acquisition and reduces financial flexibility. Management plans to bring it back below 3,0 times by end-2026, mainly through divestiture proceeds.

Is the Roundup trial finished?

The Roundup case is not closed. This legal proceeding represents one of the two binary uncertainties weighing on the stock. As long as a global settlement or a final decision does not remove the risk of additional provisions, the deep-value thesis retains a speculative character. A new provision would push the scenario toward a value trap.

Sources

No official filing is attached to this stock in the database to date. The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 4, 2026; this page was completed on September 5, 2026 at 07:11 (UTC).
Interests: no position in the stock analysed (BAYN.DE) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.